A review of quetiapine in combination with antidepressant therapy in patients with depression

Neuropsychiatric Disease and Treatment

Volumn 3, Issue 6, 2007, Pages 855-867

  Daly, Ella J ^a   Trivedi, Madhukar H ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adjunctive treatment; Atypical antipsychotics; Depression; Quetiapine

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CITALOPRAM; CLOZAPINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM SALT; MAPROTILINE; MOCLOBEMIDE; NORTRIPTYLINE; OLANZAPINE; PAROXETINE; PHENOTHIAZINE; PLACEBO; QUETIAPINE; REBOXETINE; RISPERIDONE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE; ZIPRASIDONE;

ADD ON THERAPY; ADJUVANT THERAPY; AKATHISIA; ANXIETY DISORDER; BEDTIME DOSAGE; BIPOLAR DEPRESSION; BIPOLAR MANIA; CLINICAL TRIAL; DEPRESSIVE PSYCHOSIS; DOPAMINE RELEASE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; HYPOMANIA; LABORATORY TEST; LITHIUM BLOOD LEVEL; LONG TERM CARE; MAJOR DEPRESSION; MAXIMUM PLASMA CONCENTRATION; MEDLINE; MENTAL DISEASE; META ANALYSIS; MONOTHERAPY; MOOD DISORDER; MORNING DOSAGE; MOTOR DYSFUNCTION; NONHUMAN; NORADRENALIN RELEASE; PARKINSONISM; PREVALENCE; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VITAL SIGN; WEIGHT GAIN;

EID: 38149003621     PISSN: 11766328     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Adityanjee, Schulz SC. 2002. Clinical use of quetiapine in disease states other than schizophrenia. J Clin Psychiatry, 63:32-8.
2. Adson DE, Kushner MG, Eiben MK, et al. 2004. Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depress Anxiety, 19:121-6.
3. American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders - text revision. Washington, DC.
4. Arvanitis LA, Miller BG, Borison RL, et al. 1997. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry, 42:233-46.
5. Baune BT, Caliskan S, Todder D. 2007. Effects of adjunctive antidepressant therapy with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with treatment-resistant depression. Hum Psychopharmacol, 22:1-9.
6. Brecher M, Zukin S, Leong R, et al. Long-term weight change with quetiapine treatment in schizophrenia: a comprehensive data review [poster] American College of Neuropsychopharmacology 43rd Annual Meeting. San Juan; 2004.
7. Calabrese JR, Keck PE, Macfadden W, et al. 2005. A randomized, doubleblind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry, 162:1351-60.
8. Cheer SM, Wagstaff AJ. 2004. Quetiapine - A review of its use in the management of schizophrenia. CNS Drugs, 18:173-99.
9. Corya SA, Williamson D, Sanger TM, et al. 2006. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress Anxiety, 23:364-72.
10. Dando TM, Keating GM. 2005. Quetiapine - A review of its use in acute mania and depression associated with bipolar disorder. Drugs, 65:2533-51.
11. Depression Guideline Panel. 1993. Clinical practice guideline. depression in primary care: volume 2: treatment of major depression. Publication no. 93-0551.: U.S. Department of Health and Human Services - Agency for Health Care Policy and Research.
12. DeVane CL, Nemeroff CB. 2001. Clinical pharmacokinetics of quetiapine - An atypical antipsychotic. Clin Pharmacokinet, 40:509-22.
13. Devarajan S, Ali J, Dursun SM. 2006. Quetiapine plus SSRI in treatment-resistant depression: possible mechanisms. Psychopharmacology, 185:402-3.
14. Doree JP, Des RJ, Lew V, et al. 2007. Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr Med Res Opin, 23:333-41.
15. Dube S, Andersen SW, Paul S, et al. 2002. Metanalysis of olanzapine-fluoxetine use in treatment-resistant depression. Eur Neuropsychopharmacol, 12:S180.
16. Dunner D, Amsterdam J, Shelton R, et al. 2003. Adjunctive ziprasidone in treatment-resistant depression: A pilot study (Abstract NR238). The 156th APA Annual Meeting, San Francisco, CA.
17. Galynker I, Khan A, Grebchenko Y, et al. 2005. Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression. J Clin Psychiatry, 66:544.
18. Gentile S. 2006. Long-term treatment with atypical antipsychotics and the risk of weight gain - A literature analysis. Drug Saf 29:303-19.
19. Goldstein J. 1996. Preclinical profile of seroquel (quetiapine): an atypical antipsychotic with clozapine-like pharmacology. In: Schizophrenia: breaking down the barriers. New York, NY. Wiley and Sons.
20. Goodwin GM, Consensus Group of the British Association of Psychopharmacology. 2003. Evidence-based guidelines for treating bipolar disorder: recommendations from the British Association for Psychopharmacology. J Psychopharmacol, 17:149-73.
21. Greden JF. 2001. The burden of disease for treatment-resistant depression. J Clin Psychiatry, 62:S26-31.
22. Greenberg PE, Kessler RC, Birnbaum HG, et al. 2003. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry, 64:1465-75.
23. Grimm SW, Status KR, Bui K. 1997. In vitro prediction of potential metabolic drug interactions for Seroquel. Schizophr Res, 24:198.
24. Grunze H. 2005. Reevaluating therapies for bipolar depression. J Clin Psychiatry, 66:17-25.
25. Harrow M, Yonan CA, Sands JR, et al. 1994. Depression in Schizophrenia-Are Neuroleptics, Akinesia, or Anhedonia Involved. Schizophr Bull, 20:327-38.
26. Hirose S, Ashby CR. 2002. An open pilot study combining risperidone and a selective serotonin reuptake inhibitor as initial antidepressant therapy. J Clin Psychiatry, 63:733-6.
27. Hirsch SR, Jolley AG. 1989. The dysphoric syndrome in schizophrenia and its implications for relapse. Br J Psychiatry, 155:46-50.
28. Hirschfeld R, Suppes T, Vieta E, et al. 2006. Quetiapine monotherapy for bipolar II depression: pooled results from two placebo-controlled studies. International Journal of Neuropsychopharmacology, 9:S237.
29. Hirschfeld RMA, Bowden CL, Gitlin MJ, et al. 2002. Practice Guidelines for the treatment of the patients with Bipolar Disorder (revision). Am J Psychiatry, 159(Suppl 4):1-50.
30. Hussain MZ, Waheed W, Hussain S, et al. 2005. A comparison of unipolar depression treatment using antidepressants alone versus using antidepressants in combination with quetiapine. Eur Neuropsychopharmacol, 15:S453.
31. Inset TR. 2006. Beyond efficacy: The STAR*D trial. Am J Psychiatry, 163:5-7.
32. Jaber M, Robinson SW, Missale C, et al. 1996. Dopamine receptors and brain function. Neuropharmacology, 35:1503-19.
33. Johnson DAW 1988. The significance of depression in the prediction of relapse in chronic-schizophrenia. Br J Psychiatry, 152:320-3.
34. Kapur S, Langlois X, Vinken P, et al. 2002. The differential effects of atypical Antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: A pharmacological analysis in rats. J Pharmacol Exp Ther, 302:1129-34.
35. Kasper S. 2004. Quetiapine is effective against anxiety and depressive symptoms in tong-term treatment of patients with schizophrenia. Depress Anxiety, 20:44-7.
36. Kasper S, Muller-Spahn F. 2000. Review of quetiapine and its clinical applications in schizophrenia. Expert Opin Pharmacother, 1:783-801.
37. Keating GM, Robinson DM. 2007. Quetiapine: a review of its use in the treatment of bipolar depression. Drugs, 67:1077-95.
38. Keck PE Jr, Strakowski SM, McElroy SL. 2000. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry, 61 (Suppl 3):4-9.
39. Keller MB. 2005. Issues in treatment-resistant depression. J Clin Psychiatry, 66:5-12.
40. Kennedy SH, Lam RW, Cohen NL, et al. 2001. Clinical guidelines for the treatment of depressive disorders IV. Medications and other biological treatments. Can J Psychiatry, 46:38S-58S.
41. Khullar A, Chokka P, Fullerton D, et al. 2006. Quetiapine as treatment of non-psychotic unipolar depression with residual symptoms: a double blind, randomized, placebo-controlled study. American Psychiatric Association annual meeting. Toronto, Canada.
42. Konstantinidis A, Hrubos W, Nimberger G, et al. 2007. Quetiapine in combination with citalopram in patients with unipolar psychotic depression. Prog Neuropsychopharmacol Biol Psychiatry, 31:242-7.
43. Lieberman JA, Perkins DO. 2002. Quetiapine: A 5-year update - Introduction. J Clin Psychiatry, 63:3-4.
44. Martin RL, Cloninger CR, Gaze SB, et al. 1985. Frequency and differential-diagnosis of depressive syndromes in schizophrenia. J Clin Psychiatry, 46:9-13.
45. Mattingly G, Ilivicky H, Canale J, et al. 2006. Quetiapine augmentation for treatment-resistant depression [poster]. The 159th Annual Meeting of the American Psychiatric Association. Toronto, Canada.
46. McIntyre AW, Gendron A, McIntyre A. 2006. Quetiapine augmentation of SSRIs/SNRIs in major depression with anxiety [poster]. The 159th Annual Meeting of the American Psychiatric Association. Toronto, Canada.
47. McIntyre RS, Trakas Y. Lin D, et al. 2003. Risk of weight gain associated with antipsychotic treatment: results from the Canadian National Outcomes Measurement Study in Schizophrenia. Can J Psychiatry, 48:689-94.
48. Meltzer HY, Casey DE, Garver DL, et al. 1999. Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. J Clin Psychiatry, 59:41-5.
49. Milev R, Abraham G, Zaheer J. 2006. Add-on quetiapine for bipolar depression: a 12-month open-label trial. Can J Psychiatry, 51:523-30.
50. Muller-Siecheneder F, Muller MJ, Hillert A, et al. 1998. Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome. J Clin Psychopharmacol, 18:111-20.
51. Murray CJ, Lopez AD. 1996. The global burden of disease. Boston, Massachusetts: Harvard School of Public Health, World Health Organization, World Bank.
52. Nagy J. 2005. Efficacy, safety and tolerability of quetiapine: short-term high doses with long-term follow-up. Int J Psychiatry Clin Pract, 9:16-21.
53. Nemeroff CB. 2005. Use of atypical antipsychotics in refractory depression and anxiety. J Clin Psychiatry, 66:13-21.
54. Nemeroff CB, Gharabawi GM, Canuso CM, et al. 2004. Augmentation with risperidone in chronic resistant depression: A double-blind placebo-controlled maintenance trial. Neuropsychopharmacology, 29:S159.
55. Nemeroff CB, Kinkead B, Goldstein J. 2002. Quetiapine: preclinical studies, pharmacokinetics, drug interactions, and dosing. J Clin Psychiatry, 63:5-11.
56. O'Connor M, Silver H. 1998. Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression. J Clin Psychopharmacol, 18:89-91.
57. Ostroff RB, Nelson JC. 1999. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J Clin Psychiatry, 60:256-9.
58. Papakostas GI, Petersen TJ, Kinrys G, et al. 2005. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J Clin Psychiatry, 66:1326-30.
59. Papakostas GI, Petersen TJ, Nierenberg AA, et al. 2004. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry, 65:217-21.
60. Papakostas GI, Shelton RC, Smith J, et al. 2007. Augmentation of antidepressants with atypical antipsychotic; medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry, 68:826-31.
61. Pathak S, Johns ES, Kowatch PA. 2005. Adjunctive quetiapine for treatment-resistant adolescent major depressive disorder: A case series. J Child Adolesc Psychopharmacol, 15:696-702.
62. Pitchot W, Ansseau M. 2001. Addition of olanzapine for treatment-resistant depression. Am J Psychiatry, 158:1737-8.
63. Rubinow DR. 2006. Treatment strategies after SSRI failure - good news and bad news. N Engl J Med, 354:1305-7.
64. Rush AJ, Trivedi M, Carmody TJ, et al. 2004. One-year clinical outcomes of depressed public sector outpatients: A benchmark for subsequent studies. Biol Psychiatry, 56:46-53.
65. Rush AJ, Trivedi MH, Wisniewski SR, et al. 2006. A Comparison of bupropion-SR, sertraline, and venlafaxine-XR following SSRI failure for depressed outpatients: a STAR*D report. N Engl J Med, 354:1231-42.
66. Sagud M, Mihaljevic-Peles A, Muck-Seler D, et al. 2006. Quetiapine augmentation in treatment-resistant depression: a naturalistic study. Psychopharmacology, 187:511-14.
67. Sajatovic M, Brescan DW, Perez DE, et al. 2001. Quetiapine alone and added to a mood stabilizer for serious mood disorders. J Clin Psychiatry, 62:728-32.
68. Sajatovic M, Mullen JA, Sweitzer DE. 2002. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. J Clin Psychiatry, 63:1156-63.
69. Schatzberg A, Nemeroff CB. 2006. Essentials of Clinical Psychopharmacology. Arlington, VA: American Psychiatric Publishing Inc.
70. Seeman P, Tallerico T, 1998. Antipsychotic drugs which elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry, 3:123-34.
71. Shelton RC, Tollefson GD, Tohen M, et al. 2001. A novel augmentation strategy for treating resistant major depression. Am J Psychiatry, 158:131-4.
72. Shelton RC, Williamson DJ, Corya SA, et al. 2005. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J Clin Psychiatry, 66:1289-97.
73. Simon JS, Nemeroff CB. 2005. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry, 66:1216-20.
74. Souery D, Amsterdam J, de Montigny C, et al. 1999. Treatment resistant depression: methodological overview and operational criteria. Eur Neuropsychopharmacol, 9:83-91.
75. Sprague DA, Loewen PS, Raymond CB. 2004. Selection of atypical anti-psychotics for the management of schizophrenia. Ann Pharmacother, 38:313-19.
76. Tarazi FI, Zhang K, Baldessarini RJ. 2001. Long-term effects of olanzapine, risperidone, and quetiapine on dopamine receptor types in regions of rat brain: Implications for antipsychotic drug treatment. J Pharmacol Exp Ther, 297:711-17.
77. Tarazi FI, Zhang KH, Baldessarini RJ. 2002. Long-term effects of olanzapine, risperidone, and quetiapine on serotonin 1A, 2A and 2C receptors in rat forebrain regions. Psychopharmacology, 161:263-70.
78. Targum S, Hassman H, Bastani B, et al. 2005. Use of quetiapine in treating nonpsychotic anxiety and depressive disorder. Schizophr Bull, 31:504-5.
79. Thase ME, Corya SA, Osuntokun O, et al. 2007. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder. J Clin Psychiatry, 68:224-36.
80. Thase ME, Rush Al. 1995. Treatment resistant depression. In: Psychopharmacology: the fourth generation of progress. New York, NY: Raven Press.
81. Thase ME, Macfadden W, Weisler RH, et al. 2006. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol, 26:600-9.
82. Tohen M, Vieta E, Calabrese J, et al. 2003. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry, 60:1079-88.
83. Tollefson GD, Sanger TM, Lu YL, et al. 1998. Depressive signs and symptoms in schizophrenia - A prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry, 55:250-8.
84. Vavrusova L. 2002. Quetiapine in the treatment of non-psychotic depression (P.2 E 037). Int J Neuropsychopharmacol, 5 (Suppl 1).
85. Vieta E, Reinares M, Corbella B, et al. 2001. Olanzapine as long-term adjunctive therapy in treatment-resistant bipolar disorder. J Clin Psychopharmacol, 21:469-73.
86. Viner MW, Chen YX, Bakshi I, et al. 2003. Low-dose risperidone augmentation of antidepressants in noupsychotic depressive disorders with suicidal ideation. J Clin Psychopharmacol, 23:104-6.
87. World Health Organization. World Health Report 2001. Mental Health: New Understanding, New Hope. Geneva, Switzerland: World Health Organization, 2001.
88. Yargic LI, Corapcioglu A, Kocabasoglu N, et al. 2004. A prospective randomized single-blind, multicenter trial comparing the efficacy and safety of paroxetine with and without quetiapine therapy in depression associated with anxiety. Int J Psychiatry Clin Pract, 8:205-11.
89. Yatham LN, Goldstein JM, Vieta E, et al. 2005. Atypical antipsychotics in bipolar depression: Potential mechanisms of action. J Clin Psychiatry, 66:40-8.
90. Zarate CA, Rothschild A, Fletcher KE, et al. 2000. Clinical predictors of acute response with quetiapine in psychotic mood disorders. J Clin Psychiatry, 61:185-9.